Market Business Insights - 27 December, 2022

As specified in our exclusive report, the global CRISPR Technology Market is projected to reach USD 8.2 billion by 2030.

The global CRISPR technology market is driven by the increasing focus of market players in CRISPR-CAS9 technology; availability of government and private funding and growing incidences related to genetic disorders are the key factors driving the market.

According to our analysts, Anti-CRISPR protein was launched in anticipation of making its way to the market because proteins can increase the accuracy of this technique. However, the market growth is likely to be fueled by the increase in research surrounding engineering novel enzymes and their related RNAs.

CRISPR technology is a straightforward but commanding tool aimed at editing the genome. This enables researchers to alter DNA sequences and further modify gene function without difficulty. It has many potential applications including preventing and preventing the spread of diseases, correcting genetic defects, and improving crops.

Impacting factor:

Rising use of CRISPR systems in microbiology, increasing government and private investment in research and development of genome editing, increasing prevalence of genetic disorders, and increasing application of CRISPR technology to improve crop production are driving the global CRISPR technology market.

Who is the Target Audience?

Contract Research Organizations

Pharmaceutical and Biopharmaceutical Companies

Biotechnology Companies

Academic and Research Institutes

Which Region Holds the Highest Share?

North America is expected to account for the largest share of the global market during the forecast period. This is attributed to increased government and private funding, the presence of major pharma and gene therapy companies, and the adoption of CRISPR in multiple applications.

Some of the key players in the CRISPR technology market are:

AstraZeneca plc., eGenesis, F. Hoffmann-La Roche Ltd., Cellectis, CRISPR Therapeutics, Addgene, Caribou Biosciences, Inc., Editas Medicine, Inc., Horizon Discovery Group plc, Danaher Corporation, Intellia Therapeutics, Inc., GenScript, Lonza, Intellia Therapeutics, Inc., Takara Bio Inc., Merck KGaA, Thermo Fisher Scientific, Inc., Inscripta, Inc., Cibus, Synthego, Mammoth Biosciences, Beam Therapeutics, PLANTeDIT, OriGene Technologies, Inc., Vertex Pharmaceuticals Incorporated, Hera BioLabs, Recombinetics, Inc.